Covid-19 vaccines—immunity, variants, boosters
DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
Antibody and B cell responses to SARS-CoV-2 infection and vaccination: the end of the beginning
As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
[HTML][HTML] A Covid-19 milestone attained—a correlate of protection for vaccines
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Predicting the efficacy of variant-modified COVID-19 vaccine boosters
Booster vaccination for the prevention of Coronavirus Disease 2019 (COVID-19) is required
to overcome loss of protection due to waning immunity and the spread of novel severe acute …
to overcome loss of protection due to waning immunity and the spread of novel severe acute …
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Vaccine protection from symptomatic SARS-CoV-2 infection has been shown to be strongly
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
[HTML][HTML] Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection
Several studies have shown that neutralizing antibody levels correlate with immune
protection from COVID-19 and have estimated the relationship between neutralizing …
protection from COVID-19 and have estimated the relationship between neutralizing …
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the …
Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
KA Pasquevich, LM Coria, A Ceballos… - Nature …, 2023 - nature.com
Abstract A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called
ARVAC CG was selected for a first in human clinical trial. Healthy male and female …
ARVAC CG was selected for a first in human clinical trial. Healthy male and female …
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
G Kenny, S O'Reilly, N Wrigley Kelly, R Negi… - Nature …, 2023 - nature.com
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from
early vaccine trials suggested binding antibody thresholds could serve as surrogate markers …
early vaccine trials suggested binding antibody thresholds could serve as surrogate markers …